Cipla share prices climbed on Friday after the company’s first-quarter results came in stronger than expected, giving the stock a lift in trading.
The company posted a consolidated net profit of ₹1,298 crore, up 10% from a year ago and ahead of the ₹1,198 crore figure analysts had forecast.
Revenue rose nearly 4% to ₹6,957 crore, signaling steady demand even as overseas markets remain uneven.
The stock responded quickly. Cipla shares rose more than 3% during the session, trading between ₹1,530 and ₹1,552 on the NSE and BSE.
Market cap hovered around ₹1.25 lakh crore by midday.
While the Nifty 50 was down almost 1%, Cipla stood out as one of the few gainers, driven by solid execution and a beat on the bottom line.
Cipla share price: Robust Q1 earnings
Cipla kept margins strong this quarter at 25.6%, coming in above both internal guidance and what most analysts were expecting.
That’s notable given ongoing pressure in some international markets.
R&D spend was ₹432 crore, around 6.2% of sales, which the company says reflects its continued focus on filings and new product development.
The India business stayed solid. Sales from the One India division crossed ₹3,000 crore for the first time, up 6% from last year.
Prescription drugs and branded formulations led the way.
In the US, revenue hit $226 million, helped by recent launches and a few high-margin products.
But not everything is smooth: brokerages like Macquarie flagged pricing pressure and delays in approvals as ongoing issues across the generic space.
Africa did well too, with revenue up 11% in dollar terms. Emerging markets and Europe also added to the overall growth picture.
Cipla’s Managing Director and CEO, Umang Vohra, emphasized consistent growth across geographies, stating:
Key therapies in the branded prescription business continue to outpace market growth. Trade generics and anchor consumer health brands maintain leadership.
What analysts say?
The market response was broadly upbeat. Investors, both institutional and retail, seemed encouraged by Cipla’s steady margin performance and strong showing in its home market.
Several brokerages pointed to the company’s tight cost management as a standout this quarter, with margins coming in above guidance, suggesting better-than-expected operating discipline.
The India and Africa segments are increasingly being seen as the main drivers of growth, especially as the US business continues to face pricing pressure and fewer new high-margin launches.
That said, analysts were generally reassured by Cipla’s cautious R&D approach and healthy cash flows, which help offset some of the volatility in the generics space.
Both Motilal Oswal and Axis Securities have maintained ‘Buy’ ratings on Cipla, with price targets of ₹1,830 and ₹1,735, respectively.
Their calls reflect confidence in the company’s strong domestic momentum and steady control over costs.
The post Cipla share price surges after Q1 results beat estimates: here’s what analysts say appeared first on Invezz